Wells Fargo’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-300
Closed -$26K 7279
2022
Q1
$26K Buy
+300
New +$26K ﹤0.01% 5927
2019
Q2
Sell
-11,160
Closed -$1K 6537
2019
Q1
$1K Sell
11,160
-59,706
-84% -$4.79M ﹤0.01% 5947
2018
Q4
$510K Buy
70,866
+61,380
+647% +$4.78M ﹤0.01% 4326
2018
Q3
$4K Buy
+9,486
New +$701K ﹤0.01% 6146
2018
Q2
Sell
-9,486
Closed -$18K 6490
2018
Q1
$18K Sell
9,486
-7,142
-43% -$544K ﹤0.01% 5828
2017
Q4
$1K Buy
+16,628
New +$1.25M ﹤0.01% 6261

Other funds holding NVS

Wells Fargo's NVS Position: Q2 2026 in Review

Wells Fargo reduced its Novartis (NVS) stake by 3.5% in Q2 2026, selling an estimated $10M and leaving 1,828,817 shares worth $287M. The position accounts for 0.05% of the portfolio, ranked #329.

Wells Fargo first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $760M in Q2 2015. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Wells Fargo held 1,828,817 shares of Novartis worth $287M as of Q2 2026.
  • Wells Fargo sold 66,860 Novartis shares in Q2 2026, an estimated $10M.
  • Novartis made up 0.05% of Wells Fargo's portfolio in Q2 2026, its #329 holding.
  • Wells Fargo first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • Wells Fargo's Novartis position peaked at $760M in Q2 2015.
  • 1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.